Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 3 17Phase NA 10Phase 1 8Phase 1/2 7Phase 2/3 4Phase 4 1

Status

Terminated 4Unknown 2Withdrawn 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 7Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 699Breast Neoplasms 629Neoplasms 582Leukemia, Myeloid, Acute 481Colorectal Neoplasms 455Multiple Myeloma 444Melanoma 424Prostatic Neoplasms 383Neoplasm Metastasis 370Pancreatic Neoplasms 361Recurrence 347Lymphoma 340Ovarian Neoplasms 322Lung Neoplasms 297Lymphoma, Non-Hodgkin 295Leukemia 287Glioblastoma 275Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Stomach Neoplasms 246Leukemia, Lymphocytic, Chronic, B-Cell 235Carcinoma, Hepatocellular 231Squamous Cell Carcinoma of Head and Neck 219Lymphoma, Large B-Cell, Diffuse 217Myelodysplastic Syndromes 212Carcinoma, Renal Cell 210Lymphoma, Follicular 183Head and Neck Neoplasms 172Brain Neoplasms 169Triple Negative Breast Neoplasms 167Lymphoma, Mantle-Cell 167

Interventions

Trastuzumab 4pertuzumab 2Docetaxel 2palbociclib 1Protons 1Paclitaxel 1Letrozole 1Fulvestrant 1Fluorodeoxyglucose F18 1Enfuvirtide 1Doxorubicin 1Cyclophosphamide 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × HER2-positive Breast Cancer × Clear all
NCT04273555 2026-02-06

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

University of Alabama at Birmingham

Phase 1/2 Withdrawn
Breast

HER2-positive Breast Cancer

NCT05555251 2024-12-16

CONTRAST

BioInvent International AB

Phase 1/2 Terminated
18 enrolled
BreastGastrointestinal

HER2-positive Breast Cancer

NCT03709082 2024-03-05

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

University of Kansas Medical Center

Phase 1/2 Terminated
3 enrolled
Breast

HER2-positive Breast Cancer

NCT04170595 2021-03-03

Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection

Genor Biopharma Co., Ltd.

Phase 1/2 Unknown
132 enrolled
Breast

HER2-positive Breast Cancer

NCT03881878 2019-03-21

TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery

Samsung Medical Center

Phase 1/2 Unknown
67 enrolled
Breast

HER2-positive Breast Cancer

NCT02379585 2018-04-24

STEFNE

Western Regional Medical Center

Phase 1/2 Terminated
8 enrolled 1 chart
Breast

HER2-positive Breast Cancer

NCT02345772 2018-02-20

Neohttp

Western Regional Medical Center

Phase 1/2 Terminated
4 enrolled 1 chart
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡